Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

BACKGROUND: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer. METHODS:...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Mateo, Joaquin, Porta, Nuria, Bianchini, Diletta, McGovern, Ursula, Elliott, Tony, Jones, Robert, Syndikus, Isabel, Ralph, Christy, Jain, Suneil, Varughese, Mohini, Parikh, Omi, Crabb, Simon, Robinson, Angus, McLaren, Duncan, Birtle, Alison, Tanguay, Jacob, Miranda, Susana, Figueiredo, Ines, Seed, George, Bertan, Claudia, Flohr, Penny, Ebbs, Berni, Rescigno, Pasquale, Fowler, Gemma, Ferreira, Ana, Riisnaes, Ruth, Pereira, Rita, Curcean, Andra, Chandler, Robert, Clarke, Matthew, Gurel, Bora, Crespo, Mateus, Nava Rodrigues, Daniel, Sandhu, Shahneen, Espinasse, Aude, Chatfield, Peter, Tunariu, Nina, Yuan, Wei, Hall, Emma, Carreira, Suzanne, de Bono, Johann S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lancet Pub. Group 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941219/
https://ncbi.nlm.nih.gov/pubmed/31806540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(19)30684-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi